(Q31430709)

English

Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 July 2017

Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]. (English)

1 reference

Europe PubMed Central

2 July 2017

author name string

D L Taylor

1

1 reference

Europe PubMed Central

2 July 2017

P S Ahmed

2

1 reference

Europe PubMed Central

2 July 2017

A S Tyms

3

1 reference

Europe PubMed Central

2 July 2017

L J Wood

4

1 reference

Europe PubMed Central

2 July 2017

L A Kelly

5

1 reference

Europe PubMed Central

2 July 2017

P Chambers

6

1 reference

Europe PubMed Central

2 July 2017

J Clarke

7

1 reference

Europe PubMed Central

2 July 2017

J Bedard

8

1 reference

Europe PubMed Central

2 July 2017

T L Bowlin

9

1 reference

Europe PubMed Central

2 July 2017

R F Rando

10

1 reference

Europe PubMed Central

2 July 2017

publication date

1 July 2000

1 reference

Europe PubMed Central

2 July 2017

Antiviral Chemistry & Chemotherapy

1 reference

Europe PubMed Central

2 July 2017

11

1 reference

Europe PubMed Central

2 July 2017

291-301

1 reference

Europe PubMed Central

2 July 2017

4

1 reference

Europe PubMed Central

2 July 2017

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

A three-dimensional model to analyze drug-drug interactions

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

Strategic design and three-dimensional analysis of antiviral drug combinations

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100405

21 January 2018

Identifiers

10.1177/095632020001100405

1 reference

Europe PubMed Central

2 July 2017

1 reference

Europe PubMed Central

2 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31430709&oldid=1543860610"